Nephropathy associated with use of a Chinese herbal product containing aristolochic acid

Winnie Chau, Richard Ross, Jordan Y Z Li, Tuck Y Yong, Sonja Klebe and Jeffrey A Barbara
Med J Aust 2011; 194 (7): 367-368.

Clinical record

Please login with your free MJA account to view this article in full

  • Winnie Chau1
  • Richard Ross2
  • Jordan Y Z Li1,3
  • Tuck Y Yong1,3
  • Sonja Klebe3,4
  • Jeffrey A Barbara1,3

  • 1 Flinders Medical Centre, Adelaide, SA.
  • 2 The Alfred Hospital, Melbourne, VIC.
  • 3 Flinders University, Adelaide, SA.
  • 4 SA Pathology, Adelaide, SA.

Competing interests:

None identified.

  • 1. Sorenson WR, Sullivan D. Determination of aristolochic acid I in botanicals and dietary supplements potentially contaminated with aristolochic acid I using LC-UV with confirmation by LC/MS: collaborative study. J AOAC Int 2007; 90: 925-933.
  • 2. MacLennan AH, Myers SP, Taylor AW. The continuing use of complementary and alternative medicine in South Australia: costs and beliefs in 2004. Med J Aust 2006; 184: 27-31. <MJA full text>
  • 3. Chang CH, Wang YM, Yang AH, Chiang SS. Rapidly progressive interstitial renal fibrosis associated with Chinese herbal medications. Am J Nephrol 2001; 21: 441-448.
  • 4. Vanherweghem JL, Depierreux M, Tielemans C, et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993; 341: 387-391.
  • 5. Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: a worldwide problem. Kidney Int 2008; 74: 158-169.
  • 6. Gold LS, Slone TH. Aristolochic acid, an herbal carcinogen, sold on the web after FDA alert. N Engl J Med 2003; 349: 1576-1577.
  • 7. Nortier JL, Martinez MC, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000; 342: 1686-1692.
  • 8. Schmeiser HH, Bieler CA, Wiessler M, et al. Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res 1996; 56: 2025-2028.
  • 9. Cosyns JP, Jadoul M, Squifflet JP, et al. Urothelial lesions in Chinese-herb nephropathy. Am J Kidney Dis 1999; 33: 1011-1017.
  • 10. Pozdzik AA, Salmon IJ, Debelle FD, et al. Aristolochic acid induces proximal tubule apoptosis and epithelial to mesenchymal transformation. Kidney Int 2008; 73: 595-607.
  • 11. Martinez MC, Nortier J, Vereerstraeten P, Vanherweghem JL. Steroid therapy in chronic interstitial renal fibrosis: the case of Chinese-herb nephropathy. Nephrol Dial Transplant 2002; 17: 2033-2034.
  • 12. Reginster F, Jadoul M, van Ypersele de Strihou C. Chinese herbs nephropathy presentation, natural history and fate after transplantation. Nephrol Dial Transplant 1997; 12: 81-86.
  • 13. Martinez MC, Nortier J, Vereerstraeten P, Vanherweghem JL. Progression rate of Chinese herb nephropathy: impact of Aristolochia fangchi ingested dose. Nephrol Dial Transplant 2002; 17: 408-412.
  • 14. Newall CA, Anderson LA, Phillipson JD. Herbal medicines: a guide for health care professionals. London: The Pharmaceutical Press, 1996.
  • 15. Laing C, Hamour S, Sheaff M, et al. Chinese herbal uropathy and nephropathy. Lancet 2006; 368: 338.
  • 16. Colson CR, De Broe ME. Kidney injury from alternative medicines. Adv Chronic Kidney Dis 2005; 12: 261-275.
  • 17. Therapeutic Goods Administration. The regulation of complementary medicines in Australia — an overview. Canberra: Australian Government Department of Health and Ageing, 2006. (accessed Feb 2011).
  • 18. Therapeutic Goods Administration. Aristolochia alert for practitioners. Canberra: Australian Government Department of Health and Ageing, 2001. (accessed Feb 2011).
  • 19. Therapeutic Goods Administration. Long dan xie gan wan pill medicine recall. Canberra: Australian Government Department of Health and Ageing, 2002. (accessed Feb 2011).
  • 20. Cheung TP, Xue C, Leung K, et al. Aristolochic acids detected in some raw Chinese medicinal herbs and manufactured herbal products — a consequence of inappropriate nomenclature and imprecise labelling? Clin Toxicol (Phila) 2006; 44: 371-378.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.